Table 3 KEGG pathways responded to CPA in GL261(B6) tumors

Gene Count

%

P-Value

 Immuno-stimulatory signaling pathways

mmu04060:Cytokine-cytokine receptor interaction

105

5.05

1.36E-30

mmu04142:Lysosome

50

2.41

4.61E-14

mmu04514:Cell adhesion molecules (CAMs)

55

2.65

5.33E-12

mmu04062:Chemokine signaling pathway

59

2.84

7.45E-11

mmu04630:Jak-STAT signaling pathway

50

2.41

1.51E-09

mmu04620:Toll-like receptor signaling pathway

38

1.83

1.71E-09

mmu04512:ECM-receptor interaction

34

1.64

2.09E-09

mmu04621:NOD-like receptor signaling pathway

27

1.30

2.96E-08

mmu04612:Antigen processing and presentation

32

1.54

4.18E-07

mmu04510:Focal adhesion

53

2.55

9.28E-07

mmu04210:Apoptosis

29

1.40

5.42E-06

mmu04610:Complement and coagulation cascades

25

1.20

2.82E-05

mmu05340:Primary immunodeficiency

16

0.77

2.88E-05

mmu04670:Leukocyte transendothelial migration

33

1.59

7.23E-05

 Immune effector activation pathway

mmu04650:Natural killer cell mediated cytotoxicity

56

2.69

7.15E-18

mmu04660:T cell receptor signaling pathway

39

1.88

1.13E-07

mmu04662:B cell receptor signaling pathway

30

1.44

2.18E-07

 Pathways in immune related disease

mmu04640:Hematopoietic cell lineage

45

2.17

1.28E-17

mmu05332:Graft-versus-host disease

31

1.49

3.57E-12

mmu04940:Type I diabetes mellitus

28

1.35

9.06E-09

mmu05330:Allograft rejection

26

1.25

2.82E-08

mmu05416:Viral myocarditis

31

1.49

3.05E-06

mmu04672:Intestinal immune network for IgA production

21

1.01

1.16E-05

mmu05320:Autoimmune thyroid disease

25

1.20

1.30E-05

mmu05322:Systemic lupus erythematosus

29

1.40

1.65E-04

 Tumor cell essential function pathways

mmu00100: Steroid biosynthesis

10

1.28

1.45E-09

mmu00900: Terpenoid backbone biosynthesis

8

1.02

1.80E-07

mmu03030: DNA replication

10

1.28

2.41E-06

mmu00240: Pyrimidine metabolism

14

1.79

2.95E-05

mmu04110: Cell cycle

16

2.04

4.15E-05